Research programme: eye disorder therapeutics - Altheos

Drug Profile

Research programme: eye disorder therapeutics - Altheos

Alternative Names: AK 138; AK 138 series; ATS8535

Latest Information Update: 10 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asahi Kasei Pharma Corp
  • Developer Altheos
  • Class
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glaucoma; Ocular hypertension

Most Recent Events

  • 10 Feb 2012 Preclinical development is ongoing in USA
  • 05 Apr 2010 ATS 907 and the AK 138 series licensed to Altheos
  • 05 Apr 2010 Preclinical trials in Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top